Vascular Stent Market: as MicroPort Coronary surpasses 10 million cumulative global drug-eluting stent implantations, a milestone confirming Chinese manufacturers have achieved genuine global commercial scale, the strategic centre of gravity in this market is shifting from incremental drug-eluting stent refinement toward entirely new anatomical territories, with Abbott's resorbable scaffold for below-the-knee disease opening a peripheral vascular category that conventional metallic stents have never adequately served.

The global vascular stent market size was USD 12.16 Billion in 2025 and is expected to register a revenue CAGR of 6.5% during the forecast period. Market revenue growth is driven by factors such as drug-eluting stent technology generation advances sustaining premium segment growth in coronary artery disease management, bioresorbable scaffold clinical programme revival extending resorbable stent technology into new anatomical territories, and Chinese and Indian stent manufacturer global commercial scale expansion reshaping international market share dynamics. The first driving factor is drug-eluting stent technology generation advances, which sustain premium segment growth as manufacturers introduce next-generation platforms optimised for increasingly complex coronary anatomy. Drug-eluting stents account for a substantial share of total 2025 market revenue, reflecting this category's continued position as the standard of care for the majority of percutaneous coronary intervention procedures. The second driving factor is bioresorbable scaffold clinical programme revival, as manufacturers reintroduce resorbable stent technology with improved designs addressing the safety concerns that limited earlier-generation bioresorbable scaffolds. The third driving factor is Chinese and Indian stent manufacturer global commercial scale expansion, as these manufacturers extend regulatory approval and distribution reach well beyond their historical domestic markets. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single resorbable scaffold approval for an anatomical territory that conventional metallic stents have never adequately served converts an entire underserved patient population into a newly addressable market, which lets the approved manufacturer capture first-mover revenue across a category with limited established competition rather than competing for share within an already mature coronary stent market. Because conventional metallic stents deployed below the knee face genuinely high fracture and restenosis rates given the small, calcified, and mechanically dynamic tibial vessels in this territory, a resorbable scaffold that provides temporary support while drug elution inhibits neointimal hyperplasia, then disappears entirely, directly addresses a clinical limitation that metallic stent technology has never adequately solved, opening an underserved anatomical territory to stent-based intervention for the first time. As a result, demand and revenue share in the peripheral vascular segment are concentrating around the specific below-the-knee resorbable scaffold category this approval creates, and the forecast reflects this anatomical-territory expansion as a distinct driver of the market's newest growth vector. For instance, in April 2024, Abbott Laboratories received FDA approval for its Esprit BTK Everolimus-Eluting Resorbable Scaffold System for chronic limb-threatening ischemia in below-the-knee arteries, the first FDA-approved resorbable peripheral stent, addressing a below-the-knee patient population that faces amputation within 12 months without successful revascularisation. These are some of the key factors driving revenue growth of the market.

Because coronary stent procurement in major markets including China's volume-based procurement programme and comparable national tender systems continues applying substantial downward pricing pressure, manufacturers face a genuinely more constrained per-unit revenue environment than in prior years even as underlying procedure volume continues growing.

Continued physician caution regarding earlier-generation bioresorbable scaffold safety signals is a second constraint, since earlier bioresorbable vascular scaffold generations demonstrated elevated thrombosis risk that led to their market withdrawal, and this historical safety experience continues shaping physician evaluation of newer-generation resorbable platforms even where design improvements specifically address the earlier safety concerns.

Below-the-knee procedural complexity and reimbursement pathway development are a third constraint, since newer peripheral resorbable scaffold technology requires reimbursement pathway clarity and procedural training investment before broader adoption can scale beyond the specialist centres where early clinical experience is concentrated.

These factors substantially limit vascular stent market growth over the forecast period.

The clearest driver of demand is drug-eluting stent technology generation advances, which sustain premium segment growth as manufacturers introduce next-generation platforms optimised for increasingly complex coronary anatomy. A drug-eluting stent's clinical value depends significantly on its deliverability through tortuous, calcified coronary anatomy and its drug elution profile's ability to inhibit restenosis, so each successive platform generation targeting improved deliverability and safety directly expands the range of complex lesion presentations physicians can treat with confidence. Drug-eluting stents account for a substantial share of total 2025 market revenue, and in May 2024, Abbott launched its XIENCE Sierra Everolimus-Eluting Coronary Stent System in India, extending the next-generation XIENCE family specifically for complex coronary anatomy into one of the world's largest and fastest-growing interventional cardiology markets. The effect on the market is that premium drug-eluting stent platforms continue capturing share through successive generation launches targeting increasingly complex anatomical presentations across both established and emerging markets. These are some of the key factors driving revenue growth of the market.

The second driver is bioresorbable scaffold clinical programme revival, as manufacturers reintroduce resorbable stent technology with improved designs addressing the safety concerns that limited earlier-generation bioresorbable scaffolds. Earlier bioresorbable vascular scaffold generations demonstrated elevated thrombosis risk that led to their market withdrawal, so newer-generation resorbable platforms specifically engineered to address these earlier safety limitations represent a genuinely different risk profile that clinical programmes must re-establish through dedicated trial evidence. In April 2024, Abbott received FDA approval for its Esprit BTK Everolimus-Eluting Resorbable Scaffold System for chronic limb-threatening ischemia in below-the-knee arteries, the first FDA-approved resorbable peripheral stent, representing a genuinely new clinical application for resorbable scaffold technology beyond its earlier coronary-focused development history. The effect on the market is that bioresorbable scaffold technology is establishing new anatomical territory credibility specifically in peripheral applications, separate from its more contested coronary application history. These are some of the key factors driving revenue growth of the market.

Abbott's Esprit BTK resorbable scaffold, FDA-approved in April 2024, addresses a below-the-knee chronic limb-threatening ischemia population where patients who do not receive successful revascularisation face amputation within 12 months. Conventional metallic stents have never adequately served this small, calcified, mechanically dynamic tibial vessel territory.

The third driver is Chinese and Indian stent manufacturer global commercial scale expansion, as these manufacturers extend regulatory approval and distribution reach well beyond their historical domestic markets into established international regions. A manufacturer that has achieved substantial domestic implantation scale and manufacturing efficiency in its home market gains genuine cost and production capacity advantages when pursuing international regulatory approval and distribution expansion, converting domestic scale into international commercial reach. In October 2025, MicroPort Coronary announced its cumulative global drug-eluting stent implantation had surpassed 10 million units, a milestone confirming the company's global commercial scale as a Chinese drug-eluting stent manufacturer, while Sahajanand Medical Technologies separately received Therapeutic Goods Administration approval for its Supraflex Cruz drug-eluting stent in Australia. The effect on the market is that Chinese and Indian manufacturers are establishing genuine international commercial credibility, reshaping competitive dynamics in markets historically dominated by established Western manufacturers. These are some of the key factors driving revenue growth of the market.

However, the vascular stent market faces severe adoption constraints from pricing pressure across major national tender and reimbursement systems compressing per-unit stent revenue, and continued physician caution regarding earlier-generation bioresorbable scaffold safety signals affecting broader adoption of newer resorbable platforms.

Because coronary stent procurement in major markets including China's volume-based procurement programme and comparable national tender systems continues applying substantial downward pricing pressure, manufacturers including MicroPort Coronary and Sahajanand face a genuinely more constrained per-unit revenue environment than in prior years even as underlying procedure volume and international expansion continue growing.

Continued physician caution regarding earlier-generation bioresorbable scaffold safety signals compounds this, since earlier bioresorbable vascular scaffold generations demonstrated elevated thrombosis risk that led to their market withdrawal, and this historical safety experience continues shaping physician evaluation of newer-generation resorbable platforms like Abbott's Esprit BTK even where design improvements specifically address the earlier safety concerns.

Below-the-knee procedural complexity and reimbursement pathway development are the third constraint, since newer peripheral resorbable scaffold technology requires reimbursement pathway clarity and procedural training investment before broader adoption can scale beyond the specialist centres where early clinical experience is concentrated.

These factors substantially limit vascular stent market growth over the forecast period.

Based on product type, the global vascular stent market is segmented into drug-eluting stents, bare-metal stents, bioresorbable vascular scaffolds, and self-expanding peripheral stents. Drug-eluting stents hold the largest revenue share, because they remain the standard of care for the majority of percutaneous coronary intervention procedures given their demonstrated restenosis reduction relative to bare-metal alternatives, which suits a market where the most clinically established technology commands the largest revenue category. Bare-metal stents remain a lower-cost alternative for select clinical presentations. Bioresorbable vascular scaffolds are expected to register the fastest revenue growth rate in the global vascular stent market over the forecast period, driven by Abbott's Esprit BTK opening below-the-knee peripheral applications to resorbable scaffold technology for the first time.

Based on material, the global vascular stent market is segmented into stainless steel, cobalt-chromium alloy, and biodegradable polymers. Cobalt-chromium alloy holds the largest revenue share, because it enables thinner stent struts without sacrificing radial strength, a design advantage underlying most current-generation drug-eluting stent platforms including Abbott's XIENCE Sierra. Biodegradable polymers are expected to register the fastest revenue growth rate in the global vascular stent market over the forecast period, driven by continued bioresorbable scaffold clinical programme expansion into both coronary and peripheral applications.

Percutaneous coronary intervention procedure is expected to account for the largest revenue share in the global vascular stent market during the forecast period

Based on procedure, the global vascular stent market is segmented into percutaneous coronary intervention, peripheral artery disease intervention, carotid artery stenting, and endovascular aortic aneurysm repair. Percutaneous coronary intervention holds the largest revenue share, reflecting the concentration of drug-eluting stent procedure volume within coronary artery disease treatment specifically. Peripheral artery disease intervention is expected to register the fastest revenue growth rate in the global vascular stent market over the forecast period, driven by Abbott's Esprit BTK expanding the peripheral procedure population to below-the-knee chronic limb-threatening ischemia patients specifically.

Based on regional analysis, the vascular stent market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA clearance activity and interventional cardiology procedure volume creates the deepest and most technologically advanced stent demand globally, and because Abbott, Boston Scientific, and Medtronic all maintain their primary commercial presence in the US market. Abbott's April 2024 Esprit BTK approval specifically reinforces the depth of US-anchored peripheral vascular platform innovation. The concentration of FDA approval activity in the country also means new stent categories, including resorbable peripheral scaffolds, are typically established in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The result is steady rather than rapid growth, shaped more by EU MDR compliance requirements and national health system procurement negotiation than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent two of the largest national markets within the region, anchored by MicroPort Coronary's Chinese manufacturing scale and Sahajanand Medical Technologies' Indian commercial base extending into international markets including Australia. The region's dual role as both a major manufacturing hub and a rapidly expanding coronary intervention market leaves considerably more room for growth than in the already stent-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of advanced drug-eluting and resorbable stent platforms among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the cobalt-chromium alloy and biodegradable polymer components that Latin American device distributors depend on, an effect expected to run through 2026 and slow vascular stent adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region, with Translumina Therapeutics' September 2024 direct commercial operations launch in the UAE specifically expanding coronary stent market access across the GCC. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional cardiology infrastructure needed to support advanced stent platforms at scale.